ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

New NIH Grant Program or Young Investigators

October 8, 2010

825,000 Pounds of Yew Bark Clleced in ’91 For 10,000 Patients

March 13, 1992

Administration Seeks Authorization Bill Repealing National Cancer Act, Other NIH Special Authorities

March 8, 1985

NC-Approved Clinical Trials

June 27, 2003

In Brief: THOMAS BURKE Stepped Down As Executive Vice President And Physician-In-Chief at MD Anderson Cancer Center To Accept The New Position Of Executive Vice President of the MD Anderson Cancer Network

December 13, 2013

Obama Signs Cigarette Tax Increase Into Law

February 13, 2009